Opus: University of Bath Online Publication Store Bu08073 a Buprenorphine Analog with Partial Agonist Activity at Mu Receptors in Vitro but Long- Lasting Opioid Antagonist Activity in Vivo in Mice

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CHALLENGES FOR OPIOID RECEPTOR NOMENCLATURE

  2016cited by this paper
• Opioid receptors: toward separation of analgesic from undesirable effects.

  2013cited by this paper
• Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors

  2013cited by this paper
• Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity

  2013cited by this paper
• Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

  2012cited by this paper
• Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™

  2012cited by this paper
• The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): Characterization of the In Vitro Profile and In Vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward

  2011cited by this paper
• TH-030418: a potent long-acting opioid analgesic with low dependence liability

  2011cited by this paper
• Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

  2011cited by this paper
• Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

  2011cited by this paper
• Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents.

  2011cited by this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cited by this paper
• Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling

  2010cited by this paper
• Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist.

  2008cited by this paper
• Activities of mixed NOP and μ‐opioid receptor ligands

  2008cited by this paper
• Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze.

  2008cited by this paper
• Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.

  2007cited by this paper
• Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

  2007cited by this paper
• Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies

  2007cited by this paper
• Delta opioid receptor ligands modulate anxiety‐like behaviors in the rat

  2006cited by this paper
• Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse.

  2006cited by this paper
• Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.

  2005cited by this paper
• The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference.

  2005cited by this paper
• IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS

  2005cited by this paper
• Kappa opioid antagonists: Past successes and future prospects

  2005cited by this paper
• The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.

  2004cited by this paper
• Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice

  2004cited by this paper
• Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

  2004cited by this paper
• Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

  2004cited by this paper
• Buprenorphine: a unique drug with complex pharmacology.

  2004cited by this paper
• Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents.

  2004cited by this paper
• Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

  2004cited by this paper
• Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors

  2003cited by this paper
• Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats.

  2003cited by this paper
• Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

  2001cited by this paper
• Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.

  2000cited by this paper
• Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay.

  1999cited by this paper
• Comparison of the effects of [Phe1Ψ(CH2‐NH)Gly2]Nociceptin (1–13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors

  1999cited by this paper
• A comparative study of the effects of morphine in the dorsal periaqueductal gray and nucleus accumbens of rats submitted to the elevated plus-maze test

  1999cited by this paper
• A new selective antagonist of the nociceptin receptor

  1998cited by this paper
• Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

  1998cited by this paper
• Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay

  1998cited by this paper
• Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

  1997cited by this paper
• Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

  1995cited by this paper
• Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety

  1994cited by this paper
• Buprenorphine Treatment of Opiate and Cocaine Abuse: Clinical and Preclinical Studies

  1993cited by this paper
• Long term kappa-opioid receptor blockade following nor-binaltorphimine.

  1992cited by this paper
• Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.

  1992cited by this paper
• Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.

  1991cited by this paper
• Buprenorphine suppresses cocaine self-administration in rhesus monkeys.

  1989cited by this paper
• Pharmacology of opioids.

  1983cited by this paper
• The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.

  1981cited by this paper
• A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.

  1980cited by this paper
• AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

  1977cited by this paper
• The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973influential reference

• No citing papers are available for this paper.